Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study

English version České info

Background:
The Xpert MTB/RIF (Cepheid) non-laboratory-based molecular assay has potential to improve the diagnosis of tuberculosis (TB), especially in HIV-infected populations, through increased sensitivity, reduced turnaround time (2 h), and immediate identification of rifampicin (RIF) resistance. In a prospective clinical validation study we compared the performance of Xpert MTB/RIF, MTBDRplus (Hain Lifescience), LightCycler Mycobacterium Detection (LCTB) (Roche), with acid fast bacilli (AFB) smear microscopy and liquid culture on a single sputum specimen.

Methods and Findings:
Consecutive adults with suspected TB attending a primary health care clinic in Johannesburg, South Africa, were prospectively enrolled and evaluated for TB according to the guidelines of the National TB Control Programme, including assessment for smear-negative TB by chest X-ray, clinical evaluation, and HIV testing. A single sputum sample underwent routine decontamination, AFB smear microscopy, liquid culture, and phenotypic drug susceptibility testing. Residual sample was batched for molecular testing. For the 311 participants, the HIV prevalence was 70% (n = 215), with 120 (38.5%) culture-positive TB cases. Compared to liquid culture, the sensitivities of all the test methodologies, determined with a limited and potentially underpowered sample size (n = 177), were 59% (47%–71%) for smear microscopy, 76% (64%–85%) for MTBDRplus, 76% (64%–85%) for LCTB, and 86% (76%–93%) for Xpert MTB/RIF, with specificities all >97%. Among HIV+ individuals, the sensitivity of the Xpert MTB/RIF test was 84% (69%–93%), while the other molecular tests had sensitivities reduced by 6%. TB detection among smear-negative, culture-positive samples was 28% (5/18) for MTBDRplus, 22% (4/18) for LCTB, and 61% (11/18) for Xpert MTB/RIF. A few (n = 5) RIF-resistant cases were detected using the phenotypic drug susceptibility testing methodology. Xpert MTB/RIF detected four of these five cases (fifth case not tested) and two additional phenotypically sensitive cases.

Conclusions:
The Xpert MTB/RIF test has superior performance for rapid diagnosis of Mycobacterium tuberculosis over existing AFB smear microscopy and other molecular methodologies in an HIV- and TB-endemic region. Its place in the clinical diagnostic algorithm in national health programs needs exploration.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective Study. PLoS Med 8(7): e32767. doi:10.1371/journal.pmed.1001061
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001061

Souhrn

Zdroje

1. AvertingHIV AIDS 2010 HIV and AIDS in South Africa West Sussex (United Kingdom) Averting HIV and AIDS Available: http://www.avert.org/aidssouthafrica.htm. Accessed 15 June 2011

2. United States Agency for International Development 2011 South Africa HIV/AIDS health profile. Pretoria: USAID/South Africa Available: http://www.usaid.gov/our_work/global_health/aids/Countries/africa/southafrica_profile.pdf. Accessed 27 June 2011

3. World Health Organization 2009 Global tuberculosis control: epidemiology, strategy, financing Geneva World Health Organization

4. NdjekaN 2011 Policy framework for decentralization of MDR-TB services [presentation]. Aurum Institute Tembisa TB Symposium

5. CohenTMurrayMWallengrenKAlvarezGGSamuelEY 2010 The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 7 e1000296 doi:10.1371/journal.pmed.1000296

6. BarnardMAlbertHCoetzeeGO'BrienRBosmanME 2008 Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 177 787 792

7. South Africa National Health Laboratory Service 2009 Annual report 2009–2010, transformation through unity Johannesburg South Africa National Health Laboratory Service

8. van KampenSCAnthonyRMKlatserPR 2010 The realistic performance achievable with mycobacterial automated culture systems in high and low prevalence settings. BMC Infect Dis 10 93

9. SiddiqiKLambertMLWalleyJ 2003 Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 3 288 296

10. World Health Organization 2008 Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy statement Geneva World Health Organization Available: http://www.who.int/tb/features_archive/policy_statement.pdf. Accessed 15 June 2011

11. WallisRSPaiMMenziesDDohertyTMWalzlG Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375 1920 1937

12. PaiMMinionJSohnHZwerlingAPerkinsMD 2009 Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 30 701 716

13. World Health Organization 2006 Diagnostics for tuberculosis: global demand and market potential Geneva World Health Organization Available: http://apps.who.int/tdr/publications/tdr-research-publications/diagnostics-tuberculosis-global-demand/pdf/tbdi.pdf. Accessed 15 June 2011

14. Stop TB Partnership, World Health Organization 2009 Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics Geneva World Health Organization Available: http://www.stoptb.org/wg/new_diagnostics/assets/documents/BluePrintTB_annex_web.pdf. Accessed 15 June 2011

15. World Health Organization 2010 December 8 WHO endorses new rapid tuberculosis test. Available: http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/index.html. Accessed 15 June 2011

16. BoehmeCNabetaPHillemannDNicolMPShenaiS 2010 Rapid molecular detection of tuberculosis and rifampin resistance. New Engl J Med 363 1005 1015 doi:10.1056/NEJMoa0907847

17. HillemannDRüsch-GerdesSBoehmeCRichterE 2011 Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol 49 1202 1205

18. MalbrunyBLe MarrecGCourageuxKLeclercqRCattoirV 2011 Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. Int J Tuberc Lung Dis 15 553 555

19. South Africa Department of Health 2006 Tuberculosis strategic plan for South Africa 2007–2011 Johannesburg South Africa Department of Health Available: http://www.info.gov.za/view/DownloadFileAction?id=72544. Accessed 15 June 2011

20. KubicaGPDavidHL 1980 Mycobacteria. SoanenwirthACJarettL Gradwohl's clinical laboratory methods and diagnosis, Volume 2, 8th edition St. Louis Mosby 1693 1730

21. HillemannDRusch-GerdesSRichterE 2007 Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45 2635 2640

22. RachowA 2010 Detection of Mycobacterium tuberculosis using the Cepheid Xpert MTB/RIF assay: A clinical validation study from Tanzania [abstract]. 41st Union World Conference on Lung Health; 11–15 November 2010; Berlin, Germany

23. TheronGPeterJvan Zyl-SmitRMishraHStreicherE 2011 Evaluation of the Xpert(R) MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting. Am J Respir Crit Care Med E-pub ahead of print. doi: 10.1164/rccm.201101-0056OC

24. ArmandSVanhulsPDelcroixGCourcolRLemaitreN 2011 Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 49 1772 1776

25. MarloweEMNovak-WeekleySMCumpioJSharpSEMomenyMA 2011 Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 49 1621 1623

26. TelentiA 1997 Genetics of drug resistance in tuberculosis. Clin Chest Med 18 55 64

27. TelentiAHonoreNBernasconiCMarchJOrtegaA 1997 Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 35 719 723

28. HerreraLJimenezSValverdeAGarcia-ArandaMASaez-NietoJA 2003 Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996–2001). Description of new mutations in the rpoB gene and review of the literature. Int J Antimicrob Agents 21 403 408

29. LingDIFloresLLRileyLWPaiM 2008 Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 3 e1536 doi:10.1371/journal.pone.0001536

30. RichterERusch-GerdesSHillemannD 2009 Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Respir Med 3 497 510

31. AnderssonDI 2006 The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9 461 465

32. MoureRMunozLTorresMSantinMMartinR 2011 Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J Clin Microbiol 49 1137 1139

33. BIO Ventures for Global Health, 2010 The diagnostics innovation map: medical diagnostics for the unmet needs of the developing world. Available: http://www.bvgh.org/LinkClick.aspx?fileticket=-a1C6u2LE4w%3D&tabid=91. Accessed 27 June 2011

34. BoehmeCCNicolMPNabetaPMichaelJSGotuzzoE 2011 Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377 1495 505